Oral Poliovirus Vaccine (Sabin Vaccine)

A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed)

Also Known As:

Networked: 458 relevant articles (17 outcomes, 21 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Thompson, Kimberly M: 27 articles (11/2021 - 12/2006)
2.	Sutter, Roland W: 24 articles (10/2022 - 10/2004)
3.	Pallansch, Mark A: 22 articles (11/2021 - 10/2004)
4.	Duintjer Tebbens, Radboud J: 17 articles (01/2018 - 01/2008)
5.	Centers for Disease Control and Prevention (CDC): 16 articles (06/2015 - 01/2001)
6.	Burns, Cara C: 15 articles (08/2021 - 06/2011)
7.	Wassilak, Steven G F: 13 articles (08/2021 - 04/2013)
8.	Mach, Ondrej: 11 articles (10/2022 - 08/2012)
9.	Bandyopadhyay, Ananda S: 11 articles (01/2022 - 11/2015)
10.	Oberste, M Steven: 11 articles (01/2021 - 04/2013)

Related Diseases

1.	Poliomyelitis (Polio) 09/09/2022 - "Oral poliovirus vaccine (OPV) has proven to be highly effective in the global effort to eradicate poliomyelitis because of its ability to induce both humoral and intestinal immunity, ease of administration, and low cost (1). " 04/12/2007 - "After poliomyelitis has been eradicated, access to live polioviruses will be highly restricted and the use of oral poliovirus vaccine (OPV) will probably be discontinued. " 05/01/1984 - "Oral poliovirus vaccine administered during the first year of life has been effective in controlling poliomyelitis in tropical Africa." 05/01/1981 - "Oral poliovirus vaccine has eliminated paralytic poliomyelitis caused by polioviruses in many temperate-climate countries in which a large proportion of children remain unvaccinated or incompletely vaccinated. " 03/18/2023 - "To provide a basis for further optimization of the polio sequential immunization schedule, this study evaluated the effectiveness of booster immunization with one dose of bivalent oral poliovirus vaccine (bOPV) at 48 months of age after different primary polio immunization schedules. "
2.	Infections 06/01/1998 - "Serological evidence showed that the echovirus 11' infection was unable to interfere with the efficacy of oral poliovirus vaccine (OPV), since seroconversion rates of primovaccinees did not differ significantly from those in the group seroconverted also to echovirus 11' during the vaccination campaign. " 01/26/2001 - "This report summaries the results of that study, which indicate that oral poliovirus vaccine (OPV)-derived poliovirus type 2 circulated in Egypt during the 1980s and early 1990s and caused widespread infection and paralytic disease. " 05/20/2023 - "Compared to adult HIEs, infant HIEs portray characteristics of an immature gastrointestinal epithelium including significantly shorter cell height, lower epithelial barrier integrity, and lower innate immune responses to infection with an oral poliovirus vaccine. " 01/01/2023 - "This finding is probably affected by the lower oral poliovirus vaccine immunogenicity previously demonstrated in resource-limited settings, with high prevalence of chronic intestinal infections in children and other factors discussed herein. " 10/25/2014 - "Intestinal immunity induced by oral poliovirus vaccine (OPV) is imperfect and wanes with time, permitting transmission of infection by immunised children. "
3.	Glioblastoma (Glioblastoma Multiforme) 11/01/2014 - "Oncolytic immunotherapy with PVSRIPO, the type 1 live-attenuated poliovirus (PV) (Sabin) vaccine containing a human rhinovirus type 2 (HRV2) IRES, is demonstrating early promise in clinical trials with intratumoral infusion in recurrent glioblastoma (GBM). "
4.	acute flaccid myelitis 01/01/2023 - "This case series was conducted in China after a VDPV2 was detected in stool specimens from a child with acute flaccid paralysis (AFP) in Sichuan Province in 2019, 3 years after the global withdrawal of live, attenuated type 2 oral poliovirus vaccine (OPV). " 07/01/2021 - "However, the disease resurged again in the country between 2004 and 2008 due to challenge to provide sufficient oral poliovirus vaccine coverage, migration and cross border economic activities and lack of good acute flaccid paralysis surveillance. " 01/17/2015 - "A series of epidemiological investigations were conducted, both in China and Myanmar, including retrospective searches of acute flaccid paralysis (AFP) cases, oral poliovirus vaccine (OPV) coverage assessment, and investigation of contacts and healthy children. " 10/01/2004 - "To assess areas at risk for poliovirus circulation in Ecuador, we first selected provinces at highest risk based on low immunization coverage with three doses of oral poliovirus vaccine, and a low number of reported cases of acute flaccid paralysis (AFP). " 01/01/2003 - "In 2002, a poliovirus type 3, which tested as Sabin vaccine-like, was isolated from an Australian patient with acute flaccid paralysis. "
5.	Herpes Simplex 09/01/2008 - "Oral poliovirus vaccine (OPV) is reported to be effective in treatment of recurrent herpes simplex (RHS). " 12/01/1985 - "[Treatment of recurrent herpes simplex in medical personnel in a dermatology clinic using the trivalent poliomyelitis vaccine (Sabin)]." 01/01/1974 - "Preliminary report on the treatment of recurrent herpes simplex with poliomyelitis vaccine (Sabin's)."

Related Drugs and Biologics

1.	Vaccines
2.	Inactivated Poliovirus Vaccine (Salk Vaccine)
3.	Oral Poliovirus Vaccine (Sabin Vaccine)
4.	Rotavirus Vaccines
5.	Tetanus Toxoid (Vaccine, Tetanus)
6.	Antibodies
7.	Inactivated Vaccines
8.	Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (ActHIB)
9.	Neutralizing Antibodies
10.	Phosphates (Orthophosphate)

Related Therapies and Procedures

1.	Immunotherapy
2.	Oral Administration
3.	Intramuscular Injections
4.	Injections
5.	Drug Therapy (Chemotherapy)